These sales are too small to read as a bearish signal—alert only if a material insider ($1M+) opens a sale cluster or if a C-suite officer sells >$500K. Monitor any insider open-market BUY as a stronger signal.
Price Chart
Executive Summary
Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sales over a 7-day window. While the insider count is modest, the $30K aggregate amounts to only ~0.02% of the $135M market cap—well below the 0.1% materiality threshold—making these routine, non-informative sales. The company has high analyst bullishness (92% buy/strong buy), and past insider activity has been exclusively selling ($43K in the prior 30 days), suggesting ongoing diversification/vesting patterns rather than informed bearish signaling.
Key Financial Metrics
Key Facts
- Two insiders sold a combined 10,192 shares in open-market transactions totaling ~$30K.
- Sales represent only 0.02% of GNLX's $135M market cap—trivial by proportionality standards.
- Director Thomas John sold 10,000 shares (~$30K); Head of Regulatory Smalling Ralph sold 192 shares (~$563).
- No 10b5-1 plan flag noted, but the pattern is consistent with routine portfolio rebalancing given the small dollar amounts and recurring insider sales over the past 30 days.
- 92% of analysts rate the stock Buy or Strong Buy; the stock trades near recent highs at $2.93.
Financial Impact
~$30K in aggregate insider sales, which is 0.02% of market cap—immaterial.
Risk Factors
- If a larger insider (CEO/CFO) begins selling material amounts, it could signal management discomfort with valuation.
- Small pharma stocks are volatile—any regulatory or pipeline setback could amplify downside beyond what insider activity suggests.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-GNLX-1780619736520 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | Insider Cluster | $2.52 $2.53 | ▼ −0.40% | ▼ −1.52% | $1.91 (+24.21%) |
Aug 13, 2026 10w ago | Press Release | $2.74 $2.54 | ▼ −7.30% | ▼ −5.31% | $1.91 (−30.29%) |
Jun 4, 2026 20w ago | Insider Cluster | $2.93 $3.02 | ▲ +3.07% | ▲ +1.21% | $1.91 (−34.81%) |
May 11, 2026 24w ago | Insider Cluster | $2.90 $2.98 | ▲ +2.76% | ▲ +3.06% | $1.91 (−34.14%) |
Apr 29, 2026 25w ago | DEFA14A | $2.50 $3.06 | ▲ +22.40% | ▲ +16.94% | $1.91 (−23.60%) |
Mar 24, 2026 31w ago | Insider Cluster | $2.42 $2.54 | ▲ +4.96% | ▼ −3.94% | $1.91 (−21.07%) |
Mar 19, 2026 31w ago | Press Release | $2.40 $2.65 | ▲ +10.42% | ▲ +1.10% | $1.91 (−20.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers